Fibrinolytic effect of a particular glycosaminoglycan (endoglycan) per os on normals and in patients with chronic artery disease.
Endoglycan, a heparan-dermatan sulphate association, is a highly purified heparinoid extracted from porcine intestinal mucosa. The aim of our study was to investigate the fibrinolytic system in a group of healthy controls and vascular disease patients, before and after endoglycan administration "per os". All the patients had a reduced basal fibrinolytic activity. The tests carried out were PT, PTT, FDP, Euglobulin Lysis Time (ELT), fibrinogen, plasminogen, alpha 2-antiplasmin, alpha 2-macroglobulin and t-PA activity assayed with a chromogenic method. After endoglycan administration, we have shown a significant shortening of ELT with complete normalization during the treatment. A fibrinogen decrease and either plasminogen or alpha 2-antiplasmin increase was seen. This was shown in normals too, however to a lesser extent. During therapy most of the healthy subjects, but only some patients, showed increased t-PA levels. Before and during treatment, significantly higher t-PA levels were seen in the control group as compared to the patients group. Reduced t-PA release was seen in our vascular disease patients. In conclusion, endoglycan "per os" appears to exert a stimulatory effect on the fibrinolytic system.
2nd Department of Medicine, University of Padua Medical School, Italy.
G M
GM
Patrassi
A
A
Veronesi
M T
MT
Sartori
M L
ML
Viero
G
G
Boeri
A
A
Girolami
D000328:Adult; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D001780:Blood Coagulation Tests; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D012016:Reference Values; D010959:Tissue Plasminogen Activator / Q000097:blood; D000511:alpha-Macroglobulins / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D000511:alpha-Macroglobulins; C024668:plasmin-alpha(2)-macroglobulin complex; D003871:Dermatan Sulfate; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin